ES-009

N/A

Report date: 2023/08/25 20:00:42

Base Information

Drug NameES-009
Drug Alias NameES-009
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of Actionanti-Leukocyte immunoglobulin-like receptor subfamily B member 2
TargetsLeukocyte immunoglobulin-like receptor subfamily B member 2
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPreclinical
Originator CompaniesElpiscience (Shanghai) Biopharma Ltd
China Registration ClassN/A

Develop Information

Active CompaniesElpiscience (Shanghai) Biopharma LtdElpiscience Biopharma Australia Pty Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A